ROIV · NASDAQ · STOCK
Roivant Sciences (ROIV) Stock Analysis
$35.42
52W $15.99 – $42.50
52/100
$25.60B
-93.3
1.10
Is ROIV Bullish or Bearish?
Mixed.
Innellis AI committee rates Roivant Sciences (ROIV) Watch with a composite score of 52/100
, based on 6 analysts with 83% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.74 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.26 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.4x prices in significant intangible value — Value
- ROE of only -6.1% -- cheap may mean cheap for a reason — Value
- Revenue declining -67.6% YoY -- this is not a growth story right now — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 21.5% signals elevated volatility — Risk
- News sentiment is negative (-0.25 across 4 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 84%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.4x prices in significant intangible value
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -67.6% YoY -- this is not a growth story right now
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 21.5% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
49
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.25 across 4 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 50.6 to 52.3.
- Conviction changed from moderate to high.
- Committee agreement increased notably from 67% to 83%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
42.6
Neutral
MACD Histogram
-0.339
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$33.43
Resistance
$36.90
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$35.59
Below
EMA 21
$36.41
Below
EMA 50
$36.23
Below
EMA 200
$30.64
Above
Fundamental Analysis
Valuation
77
Growth
64
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-93.3×
P/B Ratio
6.04×
PEG Ratio
0.78
Dividend Yield
0.00%
52W High
$42.50
52W Low
$15.99
Quality & Growth
ROE
-662.1%
ROA
-523.3%
Gross Margin
8121.3%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
P/E ratio of -93.3 (inexpensive relative to a 15-40x range); Price-to-book of 6.0x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -6.6%; Return on assets of -5.2%; Net margin of -3534.9%; Gross margin of 81.2%; Current ratio of 16.72 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-1.13); Most recent quarter beat estimates by 22.6%; EPS growth accelerating (-52.6% -> +55.2% QoQ); Average YoY EPS growth of 21.2%; Analyst estimates falling over recent quarters
Get the Full ROIV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →